Moberg Pharma AB (publ)
STO:MOB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Moberg Pharma AB (publ)
Other Operating Expenses
Moberg Pharma AB (publ)
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Other Operating Expenses
kr681k
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Orexo AB
STO:ORX
|
Other Operating Expenses
-kr5.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-8%
|
|
|
Camurus AB
STO:CAMX
|
Other Operating Expenses
-kr10.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Other Operating Expenses
-kr6.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
34%
|
CAGR 10-Years
0%
|
|
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
Other Operating Expenses
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Other Operating Expenses
kr10.2m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
93%
|
CAGR 10-Years
N/A
|
|
Moberg Pharma AB (publ)
Glance View
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
See Also
What is Moberg Pharma AB (publ)'s Other Operating Expenses?
Other Operating Expenses
681k
SEK
Based on the financial report for Dec 31, 2025, Moberg Pharma AB (publ)'s Other Operating Expenses amounts to 681k SEK.
What is Moberg Pharma AB (publ)'s Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
-35%
Over the last year, the Other Operating Expenses growth was 1 095%. The average annual Other Operating Expenses growth rates for Moberg Pharma AB (publ) have been -34% over the past three years , -35% over the past five years .
